Search

Your search keyword '"Otsuji Toshio"' showing total 22 results
Start Over Author "Otsuji Toshio"
22 results on '"Otsuji Toshio"'

1. Phase II study of 5-fluorouracil–leucovorin plus bevacizumab for chemotherapy-naïve older or frail patients with metastatic colorectal cancer (OGSG 0802)

Author

Ohta, Takashi, Kato, Takeshi, Kawakami, Hisato, Miyake, Yasuhiro, Goto, Masahiro, Iwamoto, Shigeyoshi, Otsuji, Toshio, Nakamura, Masato, Sugimoto, Naotoshi, Okamura, Shu, Kotaka, Masahito, Tsujie, Masaki, Tokunaga, Yukihiko, Mishima, Hideyuki, Hata, Taishi, Shimokawa, Toshio, Kurokawa, Yukinori, and Satoh, Taroh

Published
2020
Full Text
View/download PDF

7. Impact of UGT1A1 genotype on overall survival in Japanese advanced colorectal cancer patients treated by irinotecan-based regimens.

Author

Ichikawa, Wataru, primary, Uehara, Keisuke, additional, Minamimura, Keisuke, additional, Tanaka, Chihiro, additional, Takii, Yasumasa, additional, Miyauchi, Hideaki, additional, Sadahiro, Sotaro, additional, Shinozaki, Katsunori, additional, Fukumoto, Kanehisa, additional, Otsuji, Toshio, additional, Kambara, Takeshi, additional, Morita, Satoshi, additional, Ando, Yuichi, additional, Arai, Miyuki, additional, Sugihara, Masahiro, additional, Sugiyama, Toru, additional, Ohashi, Yasuo, additional, and Sakata, Yuh, additional

Published
2016
Full Text
View/download PDF

8. Capecitabine and oxaliplatin combined with bevacizumab are feasible for treating selected Japanese patients at least 75 years of age with metastatic colorectal cancer

Author

Munemoto, Yoshinori, primary, Kanda, Mitsuro, additional, Ishibashi, Keiichiro, additional, Hata, Taishi, additional, Kobayashi, Michiya, additional, Hasegawa, Junichi, additional, Fukunaga, Mutsumi, additional, Takagane, Akinori, additional, Otsuji, Toshio, additional, Miyake, Yasuhiro, additional, Nagase, Michitaka, additional, Sakamoto, Junichi, additional, Matsuoka, Masaki, additional, Oba, Koji, additional, and Mishima, Hideyuki, additional

Published
2015
Full Text
View/download PDF

9. Impact of UGT1A1 genotype on prognosis in Japanese advanced colorectal cancer patients treated by irinotecan-based regimens.

Author

Ichikawa, Wataru, primary, Uehara, Keisuke, additional, Minamimura, Keisuke, additional, Tanaka, Chihiro, additional, Takii, Yasumasa, additional, Miyauchi, Hideaki, additional, Sadahiro, Sotaro, additional, Shinozaki, Katsunori, additional, Fukumoto, Kanehisa, additional, Otsuji, Toshio, additional, Kambara, Takeshi, additional, Morita, Satoshi, additional, Ando, Yuichi, additional, Okutani, Yukihiro, additional, Sugihara, Masahiro, additional, Sugiyama, Toru, additional, Ohashi, Yasuo, additional, and Sakata, Yuh, additional

Published
2015
Full Text
View/download PDF

10. Phase II study of S-1 monotherapy in patients over 75 years of age with advanced gastric cancer (OGSG0404)

Author

Imamura, Hiroshi, primary, Kishimoto, Tomono, additional, Takiuchi, Hiroya, additional, Kimura, Yutaka, additional, Morimoto, Takashi, additional, Imano, Motohiro, additional, Iijima, Shohei, additional, Yamashita, Keishi, additional, Maruyama, Kentaro, additional, Otsuji, Toshio, additional, Kurokawa, Yukinori, additional, and Furukawa, Hiroshi, additional

Published
2013
Full Text
View/download PDF

11. Prespecified Subgroup Analyses in WJOG4407G Trial, a Randomized Phase III Trial of MFOLFOX6 Plus Bevacizumab Versus Folfiri Plus Bevacizumab in First-Line Treatment for Metastatic Colorectal Cancer

Author

Hyodo Ichinosuke, Kawakami Kentaro, Hirashima Tomonori, Okabe Michio, Tamura Fumio, Shinozaki Eiji, Boku Narikazu, Suzuki Kazuya, Tamagawa Hiroshi, Yamazaki Kentaro, Morita Satoshi, Ebi Masahide, Otsuji Toshio, Ando Masahiko, Seki Nobuhiko, Yamaguchi Kensei, Takahashi Yasuo, Taku Keisei, Sato Mikio, Nakashima Koji, and Suyama Koichi

Subjects
Oncology, medicine.medical_specialty, Bevacizumab, Colorectal cancer, business.industry, Hematology, medicine.disease, First line treatment, Internal medicine, medicine, FOLFIRI, business, medicine.drug
Published
2014

12. Prospective analysis of UGT1A1 genotyping for predicting toxicities in advanced colorectal cancer (aCRC) treated with irinotecan (IRI)-based regimens: Interim safety analysis of a Japanese observational study.

Author

Ichikawa, Wataru, primary, Uehara, Keisuke, additional, Minamimura, Keisuke, additional, Tanaka, Chihiro, additional, Takii, Yasumasa, additional, Sadahiro, Sotaro, additional, Miyauchi, Hideaki, additional, Shinozaki, Katsunori, additional, Miyagaki, Takuya, additional, Otsuji, Toshio, additional, Kambara, Takeshi, additional, Morita, Satoshi, additional, Ando, Yuichi, additional, Okutani, Yukihiro, additional, Sugihara, Masahiro, additional, Sugiyama, Toru, additional, Ohashi, Yasuo, additional, and Sakata, Yuh, additional

Published
2013
Full Text
View/download PDF

13. XELOX with bevacizumab in elderly patients age 75 or older with metastatic colorectal cancer: Results of a planned interim analysis for multicenter phase II ASCA study.

Author

Ishibashi, Keiichiro, primary, Munemoto, Yoshinori, additional, Matsuoka, Masaki, additional, Hata, Taishi, additional, Kobayashi, Michiya, additional, Hasegawa, Junichi, additional, Fukunaga, Mutsumi, additional, Takagane, Akinori, additional, Otsuji, Toshio, additional, Miyake, Yasuhiro, additional, Nagase, Michitaka, additional, Oba, Koji, additional, Sakamoto, Junichi, additional, and Mishima, Hideyuki, additional

Published
2013
Full Text
View/download PDF

14. Phase II study of first-line combined chemotherapy bevacizumab with modified RPMI regimen for elderly or frail patients with unresectable or metastatic colorectal cancer (OGSG0802).

Author

Iwamoto, Shigeyoshi, primary, Kato, Takeshi, additional, Yoshida, Motoki, additional, Miyake, Yasuhiro, additional, Nakamura, Masato, additional, Satoh, Taroh, additional, Sakai, Daisuke, additional, Matsuoka, Masaki, additional, Otsuji, Toshio, additional, and Furukawa, Hiroshi, additional

Published
2013
Full Text
View/download PDF

15. Updated survival results of the randomized phase II study of S-1, oral leucovorin, and oxaliplatin combination therapy (SOL) versus mFOLFOX6 in patients with untreated metastatic colorectal cancer (mCRC).

Author

Otsuji, Toshio, primary, Yamazaki, Kentaro, additional, Ojima, Hitoshi, additional, Kuwano, Hiroyuki, additional, Kato, Takeshi, additional, Shimada, Ken, additional, Denda, Tadamichi, additional, Esaki, Taito, additional, Hyodo, Ichinosuke, additional, and Boku, Narikazu, additional

Published
2012
Full Text
View/download PDF

16. Erratum

Author

Nishiofuku, Hideyuki, primary, Tanaka, Toshihiro, additional, Aramaki, Takeshi, additional, Boku, Narikazu, additional, Inaba, Yoshitaka, additional, Sato, Yozo, additional, Matsuoka, Masaki, additional, Otsuji, Toshio, additional, Arai, Yasuaki, additional, and Kichikawa, Kimihiko, additional

Published
2011
Full Text
View/download PDF

17. A Case of Adenosquamous Carcinoma of the Sigmoid Colon with Paraaortic Lymph Node Metastasis

Author

Masuda, Tsutomu, primary, Inatsugi, Naoki, additional, Yosikawa, Shusaku, additional, Uchida, Hideki, additional, Kuge, Hiroyuki, additional, Yokotani, Tomoyo, additional, Yamaguchi, Takaya, additional, Yamaoka, Kentaro, additional, Inagaki, Mizumi, additional, Shimobayashi, Takayoshi, additional, Matsuoka, Masaki, additional, Otsuji, Toshio, additional, Morita, Kouhei, additional, and Enomoto, Hisanori, additional

Published
2011
Full Text
View/download PDF

19. Phase II study of S-1 monotherapy in patients over 75 years of age with advanced gastric cancer (OGSG0404).

Author

Imamura H, Kishimoto T, Takiuchi H, Kimura Y, Morimoto T, Imano M, Iijima S, Yamashita K, Maruyama K, Otsuji T, Kurokawa Y, and Furukawa H

Subjects
Age Factors, Aged, Aged, 80 and over, Drug Administration Schedule, Drug Combinations, Female, Follow-Up Studies, Humans, Male, Neoplasm Recurrence, Local mortality, Neoplasm Recurrence, Local pathology, Neoplasm Staging, Prognosis, Stomach Neoplasms mortality, Stomach Neoplasms pathology, Survival Rate, Antimetabolites, Antineoplastic therapeutic use, Neoplasm Recurrence, Local drug therapy, Oxonic Acid therapeutic use, Stomach Neoplasms drug therapy, Tegafur therapeutic use
Abstract

Background: S-1+cisplatin (CDDP) is the standard treatment for advanced gastric cancer (AGC) in Japan and Korea. However, the usefulness of S-1 based chemotherapy for elderly patients is unclear. Therefore, we conducted a multicenter phase II study of S-1 monotherapy for AGC in elderly patients., Materials and Methods: Chemotherapy-naïve patients aged over 75 years with AGC were enrolled. The starting dose of S-1 was determined on the basis of body surface area and modified according to the creatinine clearance value. S-1 was administered twice a day during a 4-week period followed by a 2-week rest period., Results: Thirty-five patients were enrolled. The response rate (RR) was 14.3% and the median overall survival was 14.6 months. Grade 3 or more severe adverse events consisted of anaemia (3%), neutropaenia (3%), anorexia (3%), and fatigue (6%). There were no treatment-related deaths., Conclusion: Our study indicates that S-1 monotherapy is safe and well tolerated in chemotherapy-naïve elderly patients with AGC, but exerts limited activity when given using a tailor-made dosing strategy based on renal function.

Published
2014
Full Text
View/download PDF

20. [A surgical (right lobectomy) case of liver metastasis of colon cancer after chemotherapy using mFOLFIRI and cetuximab].

Author

Shimobayashi T, Inatsugi N, Yoshikawa S, Masuda T, Uchida H, Kuge H, Yokotani T, Yamaguchi T, Kawaguchi C, Yamaoka K, Inagaki M, Matsuoka M, Tatsumi K, Saraya T, Otsuji T, Yamochi Y, Yamanishi K, Enomoto Y, Nonomura A, Sho M, and Nakajima Y

Subjects
Adenocarcinoma drug therapy, Adenocarcinoma pathology, Aged, Antibodies, Monoclonal, Humanized, Camptothecin administration & dosage, Camptothecin analogs & derivatives, Cetuximab, Combined Modality Therapy, Fluorouracil administration & dosage, Humans, Leucovorin administration & dosage, Male, Adenocarcinoma therapy, Antibodies, Monoclonal administration & dosage, Antineoplastic Agents administration & dosage, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Colonic Neoplasms pathology, Hepatectomy, Liver Neoplasms secondary, Liver Neoplasms therapy
Abstract

A man in his early seventies underwent low anterior resection and partial resection of the liver for the rectal cancer and liver metastasis. However, 4 months after the surgery, he was found to have a liver tumor at S5 and S7 by abdominal CT scan. Then, he underwent chemotherapy (mFOLFOX6), but the metastatic tumor was progressive. We selected FOLFIRI + cetuximab regimen for second-line therapy to resect the metastatic tumor. As the metastatic lesion was become smaller after 4-course of the regimen including cetuximab, we decided to perform a radical resection. We conducted a right lobectomy of the liver, and the tumor was completely resected.

Published
2010

21. [A surgical (pancreatoduodenectomy) case of lymph node metastatic recurrence of colon cancer after chemotherapy].

Author

Yamaoka K, Inatsugi N, Yoshikawa S, Masuda T, Uchida H, Kuge H, Yokotani T, Yamaguchi T, Kawaguchi C, Shimobayashi T, Inagaki M, Matsuoka M, Tatsumi K, Saraya T, Otsuji T, Yamochi Y, Yamanishi K, Enomoto Y, Nonomura A, Sho M, and Nakajima Y

Subjects
Duodenum surgery, Female, Fluorouracil therapeutic use, Humans, Leucovorin therapeutic use, Middle Aged, Neoplasm Recurrence, Local, Organoplatinum Compounds therapeutic use, Pancreatectomy, Adenocarcinoma, Papillary pathology, Adenocarcinoma, Papillary therapy, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Colonic Neoplasms pathology, Colonic Neoplasms therapy, Lymphatic Metastasis pathology, Pancreatic Neoplasms secondary, Pancreatic Neoplasms therapy
Abstract

A woman in her fifties underwent a right hemicolectomy (D3) for cancer of the ascending colon in October 2007, definitively and pathologically diagnosed as papillary adenocarcinoma invading to the subserosa, and no metastasis was detected to lymph node. But 13 months after the surgery, she was found to have a mass near the anastomosis by an abdominal CT scan. Colonoscopy showed an evaluating lesion with ulcer in the anal side of the anastomosis. We tried to resect the metastasis, but it was not resectable because of the invasion to the pancreas. The mFOLFOX regimen was effective. After the chemotherapy (6 courses), we decided to perform a radical resection. We conducted pancreatoduodenectomy in May 2009. She is still alive 12 months after surgery.

Published
2010

22. [The introduction of the clinical study in the general hospital].

Author

Matsuoka M, Otsuji T, Saraya T, Tatsumi K, Kano A, Yamochi Y, Koda E, Kuramoto R, Ikai M, Ota K, Hamakawa R, Sugioka N, Nishimoto M, Murakami T, Yamaoka K, Uchida H, Yoshikawa S, and Inatsugi N

Subjects
Clinical Trials as Topic, Humans, Patient Care Team, Hospitals
Abstract

Our hospital fights against a clinical study clearly. However, our hospital did not participate in a clinical study here. When I widened a clinical study in cooperation with the staff, I make a progress report. I started a clinical study only with a doctor first. Therefore it was recognized many problems happened and to promote a clinical study without cooperation of the work of many kinds. I studied with the staff to promote a clinical study and deepened understanding. Thereafter the clinical study was led by a nurse of the chemotherapy room; , in addition, was able to get various cooperation from a skiagrapher. When OGSG0603 began, the nurse and the pharmacist served to become the key than a doctor. I was able to promote a clinical study by cooperation of much staff. In addition, I was able to carry out the system improvement of each section by performing a clinical study.

Published
2009

Catalog

Books, media, physical & digital resources
See catalog results